Why Did Ken Griffin Buy Sweetgreen Stock?
In Q1, Ken Griffin’s Citadel Advisors purchased nearly 1.3 million…
Sell
37
ISPC Quote, Financials, Valuation and Earnings
Last price:
$1.24
Seasonality move
:
-31.56%
Day range:
$1.24 - $1.29
52-week range:
$1.02 - $11.80
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.20x
P/B ratio:
1.86x
Volume:
43.2K
Avg. volume:
45.9K
1-year change:
-83.68%
Market cap:
$3.1M
Revenue:
$9.3M
EPS (TTM):
-$10.17
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, iSpecimen has 4738.71% upside to fair value with a price target of -- per share.
ISPC vs. S&P 500
-
Over the past 5 trading days, iSpecimen has underperformed the S&P 500 by -1.16% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
iSpecimen does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
iSpecimen revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter iSpecimen reported revenues of $1.1M.
Earnings Growth
-
iSpecimen has grown year-over-year earnings for 0 quarters straight. In the most recent quarter iSpecimen reported earnings per share of -$0.71.
Enterprise value:
2.3M
EV / Invested capital:
1.39x
Price / LTM sales:
0.20x
EV / EBIT:
--
EV / Revenue:
0.29x
PEG ratio (5yr expected):
-0.02x
EV / Free cash flow:
-0.32x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$3.1M
Return On Assets:
-108.48%
Net Income Margin (TTM):
-139.65%
Return On Equity:
-249.02%
Return On Invested Capital:
-239.85%
Operating Margin:
-154.93%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $10.8M | $9.3M | $8.1M | $2.3M | $1.1M | |
| Gross Profit | $6.1M | $4.6M | $3.1M | $1.3M | $400.2K | |
| Operating Income | -$10.4M | -$11.6M | -$11.4M | -$3M | -$1.6M | |
| EBITDA | -$8.7M | -$9.1M | -$8.9M | -$2.3M | -$1.2M | |
| Diluted EPS | -$23.20 | -$25.59 | -$10.17 | -$6.36 | -$0.71 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $3.1M | $30.2M | $16M | $5.3M | $1.5M | |
| Total Assets | $5.8M | $33.3M | $21.9M | $12.5M | $6.8M | |
| Current Liabilities | $25.9M | $2M | $3.9M | $5.7M | $4.9M | |
| Total Liabilities | $37M | $5.6M | $3.9M | $5.7M | $5.2M | |
| Total Equity | -$31.2M | $27.7M | $18.1M | $6.8M | $1.7M | |
| Total Debt | $11.4M | $3.4M | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$7.3M | -$5.1M | -$7.3M | -$2.1M | -$1.1M | |
| Cash From Investing | -$11.6M | $3.5M | $42.1K | $1.9M | -- | |
| Cash From Financing | -$3.4M | -$115.7K | $5.9M | -$118.9K | -- | |
| Free Cash Flow | -$11.7M | -$8.5M | -$7.3M | -$2.4M | -$1.1M | |
ISPC
Sector
Market Cap
$3.1M
$33.4M
Price % of 52-Week High
10.51%
47.1%
Dividend Yield
0%
0%
Shareholder Yield
-68.27%
-0.6%
1-Year Price Total Return
-83.68%
-36.6%
Beta (5-Year)
--
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.25
200-day SMA
Sell
Level
$2.87
Bollinger Bands (100)
Sell
Level
1.1 - 1.84
Chaikin Money Flow
Sell
Level
-42.7M
20-day SMA
Buy
Level
$1.19
Relative Strength Index (RSI14)
Buy
Level
52.98
ADX Line
Buy
Level
19.45
Williams %R
Neutral
Level
-32.1186
50-day SMA
Buy
Level
$1.21
MACD (12, 26)
Buy
Level
0.01
25-day Aroon Oscillator
Buy
Level
20
On Balance Volume
Neutral
Level
48M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-13.9319)
Sell
CA Score
(Annual)
Level (-4.4881)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (9.2874)
Sell
Piotroski F Score
(Annual)
Level (3)
Buy
Quality Ratio Score
Level (5)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.
Stock Forecast FAQ
In the current month, ISPC has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ISPC average analyst price target in the past 3 months is --.
-
Where Will iSpecimen Stock Be In 1 Year?
According to analysts, the consensus estimate is that iSpecimen share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About iSpecimen?
Analysts are divided on their view about iSpecimen share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that iSpecimen is a Sell and believe this share price will drop from its current level to --.
-
What Is iSpecimen's Price Target?
The price target for iSpecimen over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ISPC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for iSpecimen is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of ISPC?
You can purchase shares of iSpecimen via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase iSpecimen shares.
-
What Is The iSpecimen Share Price Today?
iSpecimen was last trading at $1.24 per share. This represents the most recent stock quote for iSpecimen. Yesterday, iSpecimen closed at $1.24 per share.
-
How To Buy iSpecimen Stock Online?
In order to purchase iSpecimen stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Planet Labs’ Stock Go Next?
On 4 June 2025 Planet reported Q1 FY 2026 revenue of $66.3 million, up 10% year over…
Where Will VICI Properties Be in 5 Years?
VICI Properties (NYSE:VICI) is a real estate investment trust focused…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 40x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 49x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
73
OKLO alert for Jun 12
Oklo [OKLO] is up 1.18% over the past day.
Buy
87
SMR alert for Jun 12
NuScale Power [SMR] is up 1.08% over the past day.
Buy
53
PLAY alert for Jun 12
Dave & Buster's Entertainment [PLAY] is up 1.35% over the past day.
